{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Peta KT"],"funding":["SAMRC Extramural Unit for Stem Cell Research and Therapy","South African Medical Research Council Self-Initiated Research Grant","South African Medical Research Council University Flagship Project (SAMRC-RFA-UFSP-01-2013/STEM CELLS)","National Research Foundation Competitive Support for Unrated Researchers"],"pagination":["898-911"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10947225"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["41(7)"],"pubmed_abstract":["The prevalence of breast cancer (BC) continues to increase and is the leading cause of cancer deaths in many countries. Numerous in vitro and in vivo studies have demonstrated that 2-methoxyestradiol (2-ME) has antiproliferative and antiangiogenic effects in BC, thereby inhibiting tumour growth and metastasis. We compared the effect of 2-ME in early- and late-stage BC using a transgenic mouse model-FVB/N-Tg(MMTV-PyVT)-of spontaneously development of aggressive mammary carcinoma with lung metastasis. Mice received 100 mg/kg 2-ME treatment immediately when palpable mammary tumours were identified (early-stage BC; Experimental group 1) and 28 days after palpable mammary tumours were detected (late-stage BC; Experimental group 2). 2-ME was administered via oral gavage three times a week for 28"],"journal":["Cell biochemistry and function"],"pubmed_title":["Effect of 2-methoxyestradiol treatment on early- and late-stage breast cancer progression in a mouse model."],"pmcid":["PMC10947225"],"funding_grant_id":["114044","A1A982"],"pubmed_authors":["Ambele MA","Durandt C","Pepper MS","van Heerden MB","Peta KT","Joubert AM"],"additional_accession":[]},"is_claimable":false,"name":"Effect of 2-methoxyestradiol treatment on early- and late-stage breast cancer progression in a mouse model.","description":"The prevalence of breast cancer (BC) continues to increase and is the leading cause of cancer deaths in many countries. Numerous in vitro and in vivo studies have demonstrated that 2-methoxyestradiol (2-ME) has antiproliferative and antiangiogenic effects in BC, thereby inhibiting tumour growth and metastasis. We compared the effect of 2-ME in early- and late-stage BC using a transgenic mouse model-FVB/N-Tg(MMTV-PyVT)-of spontaneously development of aggressive mammary carcinoma with lung metastasis. Mice received 100 mg/kg 2-ME treatment immediately when palpable mammary tumours were identified (early-stage BC; Experimental group 1) and 28 days after palpable mammary tumours were detected (late-stage BC; Experimental group 2). 2-ME was administered via oral gavage three times a week for 28","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Oct","modification":"2025-05-29T22:17:12.896Z","creation":"2025-05-29T22:17:12.896Z"},"accession":"S-EPMC10947225","cross_references":{"pubmed":["37649158"],"doi":["10.1002/cbf.3842"]}}